ArticleCureus2025
Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of recurrent, platinum-resistant, high-grade serous ovarian cancer (HGSOC) remains a challenge. Novel treatment options based on antibody-drug conjugates (ADCs) are currently in clinical trials in platinum-resistant and recurrent ovarian cancer patients. Optimizing the sequential use of ADCs is an area of unmet need and of rising clinical importance. A 70-year-old with recurrent, metastatic, platinum-resistant HGSOC overexpressing TROP2 and HER2 experienced a significant response to the ADC trastuzumab deruxtecan (anti-HER2) after progression on sacituzumab govitecan (anti-TROP2). Following trastuzumab deruxtecan treatment, she experienced a remarkable and prolonged (i.e., over six months) clinical response with resolution of liver metastatic lesions and a decrease in the size of abdominal tumor masses, along with a decrease in CA-125. She has now completed eight cycles (i.e., over six months of treatment), and her disease continues to demonstrate a prolonged response to trastuzumab deruxtecan treatment. The ADC has been well tolerated at a dose of 5.4 mg/kg with no dose-limiting toxicity or need for dose reductions. HGSOC patients with chemotherapy and sacituzumab govitecan-resistant disease may experience durable responses with the sequential use of trastuzumab deruxtecan. ADCs with a similar cytotoxic payload but targeting a different antigen may represent effective treatment options in patients with HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.